RCMI Coordinating Center (RCMI CC) Header Logo

Connection

M. Neal Guentzel to Interferon-gamma

This is a "connection" page, showing publications M. Neal Guentzel has written about Interferon-gamma.
Connection Strength

0.679
  1. Nallaparaju KC, Yu JJ, Rodriguez SA, Zogaj X, Manam S, Guentzel MN, Seshu J, Murthy AK, Chambers JP, Klose KE, Arulanandam BP. Evasion of IFN-? signaling by Francisella novicida is dependent upon Francisella outer membrane protein C. PLoS One. 2011 Mar 31; 6(3):e18201.
    View in: PubMed
    Score: 0.089
  2. Jupelli M, Selby DM, Guentzel MN, Chambers JP, Forsthuber TG, Zhong G, Murthy AK, Arulanandam BP. The contribution of interleukin-12/interferon-gamma axis in protection against neonatal pulmonary Chlamydia muridarum challenge. J Interferon Cytokine Res. 2010 Jun; 30(6):407-15.
    View in: PubMed
    Score: 0.084
  3. Powell HJ, Cong Y, Yu JJ, Guentzel MN, Berton MT, Klose KE, Murthy AK, Arulanandam BP. CD4+ T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection. Immunol Cell Biol. 2008 Aug-Sep; 86(6):515-22.
    View in: PubMed
    Score: 0.072
  4. Jupelli M, Guentzel MN, Meier PA, Zhong G, Murthy AK, Arulanandam BP. Endogenous IFN-gamma production is induced and required for protective immunity against pulmonary chlamydial infection in neonatal mice. J Immunol. 2008 Mar 15; 180(6):4148-55.
    View in: PubMed
    Score: 0.072
  5. Li W, Murthy AK, Guentzel MN, Seshu J, Forsthuber TG, Zhong G, Arulanandam BP. Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection. J Immunol. 2008 Mar 01; 180(5):3375-82.
    View in: PubMed
    Score: 0.072
  6. Wali S, Gupta R, Yu JJ, Lanka GKK, Chambers JP, Guentzel MN, Zhong G, Murthy AK, Arulanandam BP. Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs. Immunol Cell Biol. 2017 05; 95(5):454-460.
    View in: PubMed
    Score: 0.033
  7. Gupta R, Arkatkar T, Keck J, Koundinya GK, Castillo K, Hobel S, Chambers JP, Yu JJ, Guentzel MN, Aigner A, Christenson LK, Arulanandam BP. Antigen specific immune response in Chlamydia muridarum genital infection is dependent on murine microRNAs-155 and -182. Oncotarget. 2016 10 04; 7(40):64726-64742.
    View in: PubMed
    Score: 0.032
  8. Cunningham AL, Guentzel MN, Yu JJ, Hung CY, Forsthuber TG, Navara CS, Yagita H, Williams IR, Klose KE, Eaves-Pyles TD, Arulanandam BP. M-Cells Contribute to the Entry of an Oral Vaccine but Are Not Essential for the Subsequent Induction of Protective Immunity against Francisella tularensis. PLoS One. 2016; 11(4):e0153402.
    View in: PubMed
    Score: 0.031
  9. Lanka GK, Yu JJ, Gong S, Gupta R, Mustafa SB, Murthy AK, Zhong G, Chambers JP, Guentzel MN, Arulanandam BP. IgA modulates respiratory dysfunction as a sequela to pulmonary chlamydial infection as neonates. Pathog Dis. 2016 Apr; 74(3).
    View in: PubMed
    Score: 0.031
  10. Li W, Murthy AK, Lanka GK, Chetty SL, Yu JJ, Chambers JP, Zhong G, Forsthuber TG, Guentzel MN, Arulanandam BP. A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice. Vaccine. 2013 Nov 19; 31(48):5722-8.
    View in: PubMed
    Score: 0.026
  11. Signarovitz AL, Ray HJ, Yu JJ, Guentzel MN, Chambers JP, Klose KE, Arulanandam BP. Mucosal immunization with live attenuated Francisella novicida U112?iglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat model. PLoS One. 2012; 7(10):e47639.
    View in: PubMed
    Score: 0.025
  12. Chaganty BK, Murthy AK, Evani SJ, Li W, Guentzel MN, Chambers JP, Zhong G, Arulanandam BP. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine. 2010 Mar 08; 28(11):2323-9.
    View in: PubMed
    Score: 0.020
  13. Yu JJ, Goluguri T, Guentzel MN, Chambers JP, Murthy AK, Klose KE, Forsthuber TG, Arulanandam BP. Francisella tularensis T-cell antigen identification using humanized HLA-DR4 transgenic mice. Clin Vaccine Immunol. 2010 Feb; 17(2):215-22.
    View in: PubMed
    Score: 0.020
  14. Cong Y, Yu JJ, Guentzel MN, Berton MT, Seshu J, Klose KE, Arulanandam BP. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine. 2009 Sep 18; 27(41):5554-61.
    View in: PubMed
    Score: 0.020
  15. Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, Barker JR, Guentzel MN, Arulanandam BP. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol. 2009 Apr; 16(4):444-52.
    View in: PubMed
    Score: 0.019
  16. Cong Y, Jupelli M, Guentzel MN, Zhong G, Murthy AK, Arulanandam BP. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine. 2007 May 10; 25(19):3773-80.
    View in: PubMed
    Score: 0.017
  17. Murthy AK, Cong Y, Murphey C, Guentzel MN, Forsthuber TG, Zhong G, Arulanandam BP. Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele. Infect Immun. 2006 Dec; 74(12):6722-9.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support